Works citing this work

2 works

Work: A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

1. Development of criteria for the selection of therapeutic effects on metastatic renal cell carcinoma considering the factors of tumor microenvironment.

   M.N. Tillyashaykhov, Tashkent, Uzbekistan, E.V. Boyko +3

   ArticleRenal cell carcinoma treatmentExperimental and Сlinical Urology20230 citations

   ABIABI:AkademIndex/openalex/2023.article.006571

2. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment

   Saade Abdalkareem Jasim, I.M. Farber, Sara Abdalrazzaq M. Noraldeen +7

   ArticleAngiogenesis and VEGF in CancerMicrovascular Research20240 citations

   ABIABI:AkademIndex/openalex/2024.article.003439